

MANANA ELIA, M.D.

CURRICULUM VITAE

Kansas City Cancer Center
4881 NE Goodview Circle
Lee's Summit, Missouri 64064

PROFESSIONAL DESIGNATION

Licensed to Practice Medicine:

Missouri
Kansas

Board Certifications:

American Board of Internal Medicine—Hematology Diplomate	2002
American Board of Internal Medicine—Medical Oncology	2002
American Board of Internal Medicine—Diplomate	1999

EDUCATIONAL BACKGROUND

University of Kansas Medical Center Hematology / Oncology Fellowship	<i>Kansas City, KS</i> 2000-2002
Emory University School of Medicine Breast Cancer Program	<i>Atlanta, GA</i> 2001
Emory University School of Medicine Hematology/Oncology Fellowship	<i>Atlanta, GA</i> 1999-2000
Emory University School of Medicine Internal Medicine--Residency	<i>Atlanta, GA</i> 1996-1999
Tbilisi State Medical Institute Post-Doctoral Fellowship (Hepatology) / Ph.D. Program	<i>Tbilisi, Republic of Georgia</i> 1986-1990
Tbilisi State Medical Institute Internal Medicine--Residency	<i>Tbilisi, Republic of Georgia</i> 1982-1984

MANANA ELIA, M.D.
CURRICULUM VITAE—PAGE 2

Tbilisi State Medical Institute *Tbilisi, Republic of Georgia (Formerly USSR)*
Doctorate of Medicine (Summa Cum Laude) 1976-1982

PROFESSIONAL EXPERIENCE

Kansas City Cancer Centers 2002-Present
Tbilisi State Medical Institute, Tbilisi, Republic of Georgia (Formerly USSR)
Assistant Professor—Department of Medicine 1990-1992
Staff Physician 1984-1986

PUBLICATIONS AND ABSTRACTS

“Substantial Variation of NAP Estrone and Estradiol Levels Between Ducts in High Risk Women.” **Elia M.** Breast Cancer Research and Treatment. 76:1. December 2002.

“Humoral and Cellular Immunity in Alcoholic Liver Disease.” Six papers published in Soviet Medical Journals.

“Familial Mediterranean Fever.” Two papers published in Soviet Medical Journals.

**RESEARCH
(SELECTED PROTOCOLS)**

“A Phase III Trial of a Novel Etoposide BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients with Advanced Breast Cancer Previously Treated with or Resistant to an Anthracycline and Who are Taxane Resistant.” Protocol No. CA163046. Bristol-Myers-Squibb. (Sub-Investigator). 2004

“A Randomized, Double-blind, Placebo-controlled, Phase III Study in Patients with Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy with Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK 222584 or Placebo.” Protocol No.0135 (CONFIRM 1). Novartis Pharmaceuticals Corp. (Sub-Investigator). 2003.

“An Open-Label, Randomized, Multicenter Study to Evaluate the use of Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Post menopausal Women with ER+ and/or PR+ Breast Cancer, Receiving Letrozole as Adjuvant Therapy.” Protocol No. CZOL446E US32. Novartis Pharmaceuticals. (Sub-Investigator) 2003.

“A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC).” US Oncology Protocol 02-033. (Sub-Investigator). 2003.

“Randomized Phase III study of Exemestane Versus Tamoxifen For 5 Years as Adjuvant Therapy for Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients.” US Oncology Protocol 00-010, (Sub-Investigator). 2003.

“A Randomized, Open-Label, Multicenter, Phase III Trial Comparing Regimens of Adriamycin plus Cytoxan Followed by Either Taxotere or Taxotere plus Xeloda as Adjuvant Therapy for Female Patients with High-Risk Breast Cancer” US Oncology Protocol 01-062. (Sub-Investigator) 2002.

“A Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer.” Protocol BioMed 777-CLP-29. BioMedicines Inc. (Sub-Investigator) 2002.

“A Phase III Randomized Study of Lonafarnib in Combination with Paclitaxel And Carboplatin versus Placebo in Combination with Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer.” Protocol No. PO-1901. Schering-Plough Research Institute. (Sub-Investigator) 2002.

“Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-->T) with Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (AC-->TH) and With Docetaxel, Platinum Salt and Trastuzumab (TCH) in the Adjuvant Treatment of Node Positive and High Risk Node Negative Patients with Operable Breast Cancer Containing the HER2NEU Alteration” US Oncology Protocol 01-001. (Sub-Investigator). 2002

PROFESSIONAL MEMBERSHIPS

American Society of Hematology
American Society of Clinical Oncology
Kansas City Clinical Oncology Program